Delving into the Latest Updates on Pneumococcal polysaccharide vaccine 23-valent(Beijing Minhai Biological Technology Co., Ltd.) with Synapse

This retrospective matched cohort study investigated the protective effects of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) against pneumonia mortality and all-cause mortality in Japanese adults aged ≥65 years. We analyzed claims data, vaccination records, and death certificate records between October 2016 and December 2019 from 55 509 PPSV23-vaccinated individuals and 55 509 unvaccinated individuals. Cox proportional hazards analyses were performed to calculate the adjusted hazard ratios (HRs) of PPSV23 vaccination for mortality. The results showed that PPSV23 vaccination was significantly associated with a reduction in all-cause mortality (adjusted HR, 0.52; P < .001) but not pneumonia mortality (adjusted HR, 0.70; P = .374).

01 Dec 2023·Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Prognoses of patients undergoing hemodialysis administered 23-valent pneumococcal polysaccharide versus 13-valent pneumococcal protein conjugate vaccines

Article

Author: Takazono, Takahiro ; Funakoshi, Satoshi ; Nishino, Tomoya ; Hashiguchi, Junichiroh ; Kitamura, Mineaki ; Yamaguchi, Kosei ; Mukae, Hiroshi

INTRODUCTION:

Sequential vaccination with the 13-valent pneumococcal protein conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for patients undergoing hemodialysis; however, evidence for the efficacy of these pneumococcal vaccines for patients undergoing hemodialysis is limited to a single dose. We aimed to evaluate the prognosis of patients undergoing hemodialysis who received vaccination with PPSV23 alone versus sequential vaccination with PCV13 and PPSV23.

METHODS:

Patients undergoing hemodialysis who were vaccinated with PPSV23 alone (PPSV23 group) or PCV13 followed by PPSV23 (PCV13+PPSV23 group) between 2014 and 2016 were included; the observation period was three years from the first injection. Patients who underwent hemodialysis between 2011 and 2012 were included as controls. After propensity score matching using age, sex, dialysis vintage, diabetes history, pneumonia history, and serum albumin and creatinine levels, survival analysis was performed.

RESULTS:

The study included 89, 71, and 319 patients in the PPSV23, PCV13+PPSV23, and control groups, respectively. After propensity score matching, the PPSV23 and control group 1 (79 patients each) and the PCV13+PPSV23 and control group 2 (61 patients each) were compared. Significant differences were observed in the survival rate between the PPSV23 group and control group 1 (p = 0.005) but not between the PCV13+PPSV23 group and control group 2. Pneumonia-related mortality in the two vaccinated groups did not differ significantly during the observation period.

CONCLUSIONS:

Patients who received PPSV23 had a favorable prognosis; however, no positive effect was demonstrated in the PCV13+PPSV23 group.

03 May 2022·Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance

Article

Author: Glikman, Danny ; Kasis, Imad ; Viener-Well, Yonit ; Finn, Talia ; Khoury-Assi, Camellia ; Weber, Gabriel ; Bar-Yochai, Avihu ; Zbriger, Alvira ; Korenman, Zina ; Barkai, Galia ; Ben-Zvi, Haim ; Bachinski, Ahuva ; Amir, Jacob ; Sari, Mandelbaum ; Kennes, Yoram ; Glikman, Daniel ; Freimann, Sarit ; Paran, Yael ; Averbuch, Diana ; Smollan, Gill ; Gottesman, Giora ; Ephros, Moshe ; Regev-Yochay, Gili ; Grisaru-Soen, Galia ; Guri, Alex ; Rahav, Galia ; Geffen, Yuval ; Strahilevitz, Jacob ; Dagan, Ron ; Engelhard, Dan ; Temper, Violetta ; Megged, Orli ; Peretz, Avi ; Hershman, Mirit ; Mor, Meirav ; Brosh-Nissimov, Tal ; Zucker, Miriam ; Rubinstein, Uri ; Elias, Nael ; Katzir, Michal ; Reisenberg, Klaris ; Bernstein, Rita ; Maor, Yasmin ; Miron, Dan ; Assous, Marc ; Paitan, Yosi ; Embon, Alicia ; Cohen-Poradosu, Ronit ; Khakshoor, Shirley ; van der Beek, Bart Adriaan ; Schlesinger, Yechiel ; Srugo, Itzhak ; Zimchony, Oren ; Schwartz, Orna ; Miron, Danny ; Ofir-Mintzer, Hana ; Istomin, Valery ; Ben-Shimol, Shalom ; Sheindler, Yehudit ; Bar-Meir, Maskit ; Brik, Larissa ; Aviner, Shraga ; Keller, Nathan ; Stein, Michal ; Sverdlob, Olga ; Schwartz, David ; Shalit, Itamar ; Rechnitzer, Hagai ; Shaked-Mishan, Pninit ; Ztibba, Yevgenia ; Givon-Lavi, Noga ; Chowers, Michal ; Asher Kuperman, Amir ; Srugo, Isaac ; Oren, Ilana ; Weinberger, Miriam ; Benedikt, Ilana ; Bardenstein, Rita ; Chazan, Bibiana ; Sela, Shifra ; Bishara, Jihad ; Somekh, Eli ; Potasman, Israel

Abstract:

Background:

Following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in infants worldwide, overall and vaccine-type invasive pneumococcal disease (IPD) rates declined in children, with variable indirect impact on adults.

Methods:

A population-based, prospective, nationwide active surveillance of IPD in Israel, 2004–2019 (for adults ≥18 years, 2009–2019). The 7-valent PCV (PCV7)/PCV13 were implemented in Israel in July 2009/November 2010, respectively, with >90% uptake in children <2 years. The 23-valent pneumococcal polysaccharide vaccine (PPV-23) uptake among those >65 years was ~75%. For pre-PCV episodes with missing serotype, extrapolations were applied. Overall, PCV13 serotypes (VT13) and non-VT13 (NVT) incidence rate ratios (IRRs) comparing pre-PCV (2004–2008), early-PCV (2009–2011), and late-PCV13 (2016–2019) periods were calculated for different age groups.

Results:

Overall, 8614 IPD cases were recorded. IPD rates declined by 67% in children <5 and 5–17 years, comparing late-PCV13 versus pre-PCV periods (IRR [95% CI]: .33 [.27–.40] and .33 [.21–.50], respectively). For adults, comparing late-PCV13 with early-PCV periods, rates significantly declined by 53% in those aged 18–44, while rates did not decline significantly in other age groups. VT13 rates significantly declined in all ages, with decline rates ranging between 94% in children <5 years and 60% in adults ≥85 years. NVT rates significantly increased in <5-, 50–64-, and ≥65-year age groups. In the late-PCV13 period, serotypes 3, 14, and 19A remained the predominant VT13, while serotypes 8 and 12F emerged as predominant NVTs.

Conclusions:

Continuous monitoring of circulating serotypes in all ages demonstrated direct and indirect PCV effects, which are essential for the development of new vaccination strategies.

100 Deals associated with Pneumococcal polysaccharide vaccine 23-valent(Beijing Minhai Biological Technology Co., Ltd.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07AL01	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacteremia	China	Beijing Minhai Biological Technology Co., Ltd.	12 Aug 2018
Meningitis	China	Beijing Minhai Biological Technology Co., Ltd.	12 Aug 2018
Otitis Media	China	Beijing Minhai Biological Technology Co., Ltd.	12 Aug 2018
Pneumonia	China	Beijing Minhai Biological Technology Co., Ltd.	12 Aug 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Encephalitis	Phase 3	China	Beijing Minhai Biological Technology Co., Ltd.	26 Oct 2011
Pneumococcal Infections	Preclinical	China	Shenzhen Kangtai Biological Products Co., Ltd.	30 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2006	Not Applicable	HIV Infections	89	23-valent polysaccharide pneumococcal vaccination (Group 1)	rpxvkwbkli(zyhklfnfrr) = wtejpfwima iowmhxmtqp (wzggbwtpuf ) View more	-	01 Jan 2006
				23-valent polysaccharide pneumococcal vaccination (Group 2)	rpxvkwbkli(zyhklfnfrr) = sbncscrury iowmhxmtqp (wzggbwtpuf ) View more